EU Health Chair: Big Tech May Replace Big Pharma as AI Reshapes Medicine

The convergence of artificial intelligence and computational biology is transforming medicine faster than European regulators can adapt, threatening to render current pharmaceutical laws obsolete. Adam Jarubas, chair of the European Parliament’s public health committee (SANT), warns that this shift toward tech-driven research means "Big pharma may soon be replaced by big tech."

Jarubas argues that the European Union's recent focus on traditional pharmaceutical legislation may have missed the mark. While the EU has spent years negotiating a Pharmaceutical Package centered on manufacturing and supply chain dependencies—specifically regarding active pharmaceutical ingredients from Asia—the frontier of innovation has shifted toward digital drug design. Jarubas noted that in light of biofoundries and AI-driven research, the struggle over the Pharmaceutical Package may have been "a battle over yesterday’s game."

The Rise of Digital Biology

Central to this shift are "biofoundries," which integrate robotics, AI, and synthetic biology to automate the creation of new medicines. These facilities could potentially reduce the time required to develop and validate new therapies by approximately half.

Complementing this automation is the "Human Digital Twin" initiative. Presented by Professor Maciej Malawski of the SANO Centre for Computational Personalised Medicine, the project aims to develop virtual patient models. These digital twins allow researchers to simulate the progression of diseases and predict how specific patients will respond to treatments before a drug is ever administered in a clinical setting.

The Sovereignty Gap

This technological leap creates a strategic risk for the European Union. Currently, much of the foundational AI being applied to biomedicine is developed by external entities, primarily based in the United States. Jarubas warns that if Europe remains solely a regulator of these technologies rather than a creator, it will lose its pharmaceutical sovereignty. "If we fail to act now, Europe risks becoming a regulator of technologies developed elsewhere," Jarubas stated.

To counter this, Jarubas suggests that Europe must pivot from a purely regulatory mindset to one of active investment in the intersection of biology, medicine, and AI. The goal is to foster a domestic AI-biomedical ecosystem capable of competing with global tech giants.

The Regulatory Path Forward

Despite these warnings, some infrastructure is already in place. Jarubas identified the AI Act, the Data Act, and the European Health Data Space as the primary EU frameworks that should serve as the foundation for this innovation. These tools are intended to manage data privacy and AI safety while enabling the flow of information necessary for computational medicine.

What remains to be seen is whether the EU can translate these regulatory frameworks into a competitive industrial strategy. The transition from traditional chemical manufacturing to AI-driven bio-manufacturing represents a fundamental paradigm shift in how medicine is conceived, tested, and delivered to the public.